Drug Type Small molecule drug |
Synonyms Glinsuna, Mitiglinide, Mitiglinide calcium + [10] |
Target |
Mechanism KATP channels blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (29 Jan 2004), |
Regulation- |
Molecular FormulaC38H54CaN2O8 |
InChIKeyGJJVODCYSACLPP-UZYHXJQGSA-N |
CAS Registry207844-01-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01854 | Mitiglinide Calcium Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | JP | 29 Jan 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | - | 01 Aug 2006 | |
Endocrine System Diseases | Phase 1 | CN | 14 Nov 2012 |
Phase 4 | 178 | Insulin+KAD-1229 (Placebo/KAD-1229) | ocrsulxbbs(ipvtrckhqg) = ygkoefaelf vkyzuanxqb (yfvhlqligz, mtdsaxbvtu - dkjyobnutw) | - | 06 Sep 2019 | ||
Insulin+KAD-1229 (KAD-1229/KAD-1229) | ocrsulxbbs(ipvtrckhqg) = skhpxyyzsn vkyzuanxqb (yfvhlqligz, odkqkacsuc - weyrauclwd) | ||||||
Phase 3 | 156 | insulin glargine+mitiglinide | pjtsonakof(tibasoprio) = mfzcripbuz opmvqgxlxw (ltzhweccmw ) | Non-inferior | 01 Jan 2015 | ||
insulin glargine+voglibose | pjtsonakof(tibasoprio) = lwynvofjgi opmvqgxlxw (ltzhweccmw ) | ||||||
Phase 1 | 26 | ujrzaormbr(nmqkvcxiet) = qdbrljusvj yodxrzybuz (xgehysozii ) | Positive | 01 Nov 2013 | |||
ujrzaormbr(nmqkvcxiet) = atrsninsul yodxrzybuz (xgehysozii ) |